Scott P. Bruder, MD, PhD, is the Senior Vice President and Chief Science and Technology Officer of BD, where he is responsible for providing technology, strategy and development leadership to the company as it focuses on innovation and impact in medical devices, diagnostics and biosciences. He leads the Research & Development function across the Corporation, and until 2011, also led corporate strategic planning and business development.
Dr. Bruder joined BD in 2007, and has focused his efforts on identifying and developing promising technologies to address unmet health care needs and emerging life science research trends. He drives the Company’s effort to continuously improve the product development system, enhance the process of innovation, manage a diverse portfolio and $500 million operating budget, globalize the R&D function, and develop outstanding leaders around the world.
Dr. Bruder also serves on the FDA Advisory Committee for Cellular, Tissue and Gene Therapies, is a member of the New York Stem Cell Foundation’s Advisory Board, and is a Trustee of the Liberty Science Center in New Jersey. He maintains an active academic presence as an Adjunct Professor at the CWRU School of Engineering, where he Chairs the External Advisory Board in Bioengineering. He Chairs a similar Advisory Board at the Brown University School of Engineering, and also serves on the Georgia Tech Advisory Board.
Prior to joining BD, Dr. Bruder held a variety of senior executive and scientific roles. He spent eight years at Johnson & Johnson, where he developed a corporate-wide strategic plan and led the creation of Johnson & Johnson Regenerative Therapeutics, LLC, which was responsible for innovative biotechnology products. Before serving as a Worldwide Vice President at J&J, he held various other Vice President roles in basic, applied and clinical research at J&J, Anika Therapeutics, and Osiris Therapeutics, specializing in biomaterial and cell therapies.
Dr. Bruder is an accomplished researcher and innovator, with more than 20 issued and pending U.S. and international patents. He has published nearly 150 original articles, book chapters and abstracts in peer-reviewed journals, and he is a distinguished lecturer at societies, universities and industry events around the world. His pioneering work on the characterization and clinical application of human mesenchymal stem cells and recombinant growth factors earned him academic and industry acclaim, as well as numerous scientific honors. In 2011, he was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE), and was nominated for the President’s National Medal of Technology and Innovation.
Scott is a magna cum laude graduate from Brown University, and CWRU School of Medicine, where he simultaneously earned a PhD in stem cell biology. He then obtained further clinical training at Albert Einstein Medical Center and the University of Pennsylvania.